Compare CSIQ & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSIQ | TYRA |
|---|---|---|
| Founded | 2001 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.2B |
| IPO Year | 2006 | 2021 |
| Metric | CSIQ | TYRA |
|---|---|---|
| Price | $22.86 | $22.54 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $17.63 | ★ $31.20 |
| AVG Volume (30 Days) | ★ 5.5M | 570.8K |
| Earning Date | 11-13-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,899,139,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $29.96 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.57 | $6.42 |
| 52 Week High | $34.59 | $24.05 |
| Indicator | CSIQ | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 46.94 | 69.31 |
| Support Level | $22.21 | $21.66 |
| Resistance Level | $25.45 | $24.05 |
| Average True Range (ATR) | 2.17 | 1.31 |
| MACD | -0.58 | -0.05 |
| Stochastic Oscillator | 8.55 | 67.04 |
Canadian Solar Inc is a Canadian solar technology and renewable energy company. It is a manufacturer of solar photovoltaic modules, a provider of battery energy storage solutions, and a developer of utility-scale solar power and battery energy storage projects.. It operates through two business segments CSI Solar and Recurrent Energy segment. The CSI Solar segment focused on solar modules and battery energy storage manufacturing and products. Its Recurrent segment focused on utility-scale solar power and battery energy storage project development and operation. Key revenue is generated from CSI Solar segment.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.